Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyRegional therapyVisceral SurgeryDiseaseBreast CancerColon CancerEsophageal CancerGastric CancerOvarian TumorPeritoneal Carcinomatosis, SecondarySubgroupAdenocarcinoma of the esophagogastric junction (AEG)EpCAM positiveICD10C15.-C16.-C16.0C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C50.-C56C78.6MeSHBreast NeoplasmsCarcinoma, Ovarian EpithelialColorectal NeoplasmsEsophageal NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsStomach NeoplasmsSequenceAntineoplastic therapySubstanceCatumaxomabCisplatinFluorouracilNaCl 0.9%SubstanceCatumaxomabCisplatinFluorouracilNaCl 0.9%SubstanceCatumaxomabCisplatinFluorouracilNaCl 0.9%SubstanceCatumaxomabCisplatinFluorouracilNaCl 0.9%No. Substances12 RadiotherapySupportive therapySubstanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSubstanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSubstanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSubstanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateNo. Substances35Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseintraoperativTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)Increase AminotransferasesLymphopeniaPyrexia only studiesPublicationAuthorGhanipour LGötze THeiss MMDiseaseLokalisiertes oder lokal fortgeschrittenes Magen-Ca oder Karzinom des gastroösopagealen Übergangs Typ II/IIIPeritonealkarzinose, sekundärPeritonealkarzinose, sekundär, EpCAM positivOriginCologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, GermanyPREVENT - FLOT9 trial of the AIO / CAOGI / ACOUppsala University, Uppsala, SwedenProtocols in Revision 3 protocols foundCatumaxomab (10/20/50/150), Peritoneal Carcinomatosis, Secondary (PID3037 V1.0)EPIC - Fluorouracil 400, Peritoneal Carcinomatosis, Secondary (PID2709 V1.0)HIPEC - Cisplatin 75, Adenocarcinoma Esophagogastric Junction and Stomach (PID2710 V1.1)
